AP 505
Alternative Names: AP-505; B-1962Latest Information Update: 28 Aug 2024
At a glance
- Originator AP Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer; Lung cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Lung-cancer in Taiwan (Parenteral)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Liver-cancer in Taiwan (Parenteral)
- 19 Dec 2022 Tasly Biopharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in December 2022 (Parenteral. Injection) (NCT05650385)